Chardan Capital Thinks Caladrius Biosciences’ Stock is Going to Recover

By Ryan Adsit

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Caladrius Biosciences (NASDAQ: CLBS) yesterday and set a price target of $6.50. The company’s shares closed yesterday at $3.76, close to its 52-week low of $3.26.

According to, Nakae is ranked 0 out of 5 stars with an average return of -32.9% and a 20.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Asterias Biotherapeutics, Synthetic Biologics Inc, and Ritter Pharmaceuticals.

Caladrius Biosciences has an analyst consensus of Moderate Buy.

Based on Caladrius Biosciences’ latest earnings report from March 31, the company posted quarterly revenue of $7.49M and quarterly net profit of -$11.98M. In comparison, last year the company earned revenue of $5.89M and had a net profit of -$11.38M.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLBS in relation to earlier this year.

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. The companies business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.